Reference:
Yagisawa, M., Foster, P. J., Hanaki, H., & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics, 74(1), 44-73. https://doi.org/xxxxxx
Summary:
The article reviews the global response to the COVID-19 pandemic, particularly the role of ivermectin as a potential treatment. Initially regarded as ineffective, ivermectin gained attention after in vitro studies indicated it could inhibit SARS-CoV-2. Subsequent clinical trials in various countries demonstrated mixed results, leading to debates over its efficacy. As of January 2021, 91 trials were registered, with many showing promising outcomes, especially in early treatment and prevention. However, delays in funding and progress in Japan raised concerns about the drug’s timely approval. The authors advocate for broader support for ongoing research to establish ivermectin as a viable treatment option amidst ongoing vaccine supply challenges and the need for effective therapies for mild to moderate cases.